🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05325437
Recruiting Not applicable

The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients

NCT05325437 · tracked via the Priya Life Science China tracker
Sponsor
Northern Jiangsu People's Hospital
Phase
Not applicable
Started
2022-03-01
Last updated
2025-05-30

Condition(s) studied

Cirrhosis, LiverSplenectomy; StatusPortal Hypertension

Investigational drug(s) / intervention(s)

Laparoscopic splenectomy and azygoportal disconnection

Laparoscopic splenectomy and azygoportal disconnection: The laparoscopic splenectomy and azygoportal disconnection was performed by the same surgical team.

Study summary

In this study, the investigators compared the improvement of liver reserve function related indicators in patients with liver cirrhosis after laparoscopic splenectomy and azygoportal disconnection. To determine whether surgical treatment can help enhance postoperative liver reserve function and improve patient prognosis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * A clinical, radiological or histologic diagnosis of cirrhosis of any etiology * Splenomegaly with secondary hypersplenism * gastroesophageal variceal bleeding * Informed consent to participate in the study Exclusion Criteria: * Hepatocellular carcinoma or any other malignancy, * Child-Pugh grade C * Recent peptic ulcer disease * History of Hemorrhagic stroke * Pregnancy. * Uncontrolled Hypertension * Human immunodeficiency virus (HIV) infection

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinical Medical College of Yangzhou University Yangzhou Jiangsu Recruiting

More Northern Jiangsu People's Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05325437 on ClinicalTrials.gov ↗ ← All trials in China